Mortalin inhibition in experimental Parkinson's disease

Movement Disorders

Volumn 26, Issue 9, 2011, Pages 1639-1647

  Chiasserini, Davide ^a,b   Tozzi, Alessandro ^a,b   de Iure, Antonio ^a,b   Tantucci, Michela ^a   Susta, Federica ^a   Orvietani, Pier Luigi ^a   Koya, Keizo ^c   Binaglia, Luciano ^a   Calabresi, Paolo ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c Synta Pharmaceuticals Corp   (United States)

Author keywords

6 hydroxydopamine; Heat shock protein; Mitochondria; Mortalin; Parkinson's disease; Rotenone

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; HEAT SHOCK PROTEIN; MORTALIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; ELECTROPHYSIOLOGY; MALE; MEMBRANE CURRENT; MEMBRANE DEPOLARIZATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RAT;

ACTION POTENTIALS; ANIMALS; ANTIPARASITIC AGENTS; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRON TRANSPORT COMPLEX I; GENE EXPRESSION REGULATION; HSP70 HEAT-SHOCK PROTEINS; MALE; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; PROTEOMICS; PYRIDINES; RATS; RATS, WISTAR; THIAZOLES;

EID: 79961207065     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23647     Document Type: Article

References (53)

1. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med. 1998; 339: 1044-1053.
2. Janetzky B, Hauck S, Youdim MB, et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett. 1994; 169: 126-128.
3. Orth M, Schapira AH. Mitochondrial involvement in Parkinson's disease. Neurochem Int. 2002; 40: 533-541.
4. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990; 54: 823-827.
5. Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord. 2003; 9(Suppl 2): S59-S64.
6. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983; 219: 979-980.
7. Di Filippo M, Chiasserini D, Tozzi A, Picconi B, Calabresi P. Mitochondria and the link between neuroinflammation and neurodegeneration. J Alzheimers Dis. 2010; 20(Suppl 2): S369-S379.
8. Przedborski S, Jackson-Lewis V, Djaldetti R, et al. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci. 2000; 16: 135-142.
9. Sherer TB, Betarbet R, Testa CM, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003; 23: 10756-10764.
10. Glinka YY, Youdim MB. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol. 1995; 292: 329-332.
11. Ben-Shachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem. 1995; 64: 718-723.
12. Deocaris CC, Kaul SC, Wadhwa R. From proliferative to neurological role of an hsp70 stress chaperone, mortalin. Biogerontology. 2008; 9: 391-403.
13. Calabrese V, Scapagnini G, Ravagna A, Giuffrida Stella AM, Butterfield DA. Molecular chaperones and their roles in neural cell differentiation. Dev Neurosci. 2002; 24: 1-13.
14. Endo T, Yamano K. Multiple pathways for mitochondrial protein traffic. Biol Chem. 2009; 390: 723-730.
15. Becker J, Craig EA. Heat-shock proteins as molecular chaperones. Eur J Biochem. 1994; 219: 11-23.
16. Falsone SF, Kungl AJ, Rek A, Cappai R, Zangger K. The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein. J Biol Chem. 2009; 284: 31190-31199.
17. Tantucci M, Mariucci G, Taha E, et al. Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment. Neuroscience. 2009; 163: 735-740.
18. Geissler A, Rassow J, Pfanner N, Voos W. Mitochondrial import driving forces: enhanced trapping by matrix Hsp70 stimulates translocation and reduces the membrane potential dependence of loosely folded preproteins. Mol Cell Biol. 2001; 21: 7097-7104.
19. Jin J, Hulette C, Wang Y, et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics. 2006; 5: 1193-1204.
20. Xu L, Voloboueva LA, Ouyang Y, Emery JF, Giffard RG. Overexpression of mitochondrial Hsp70/Hsp75 in rat brain protects mitochondria, reduces oxidative stress, and protects from focal ischemia. J Cereb Blood Flow Metab. 2009; 29: 365-374.
21. Shi M, Jin J, Wang Y, et al. Mortalin: a protein associated with progression of Parkinson disease? J Neuropathol Exp Neurol. 2008; 67: 117-124.
22. Jin J, Li GJ, Davis J, et al. Identification of novel proteins associated with both alpha-synuclein and DJ-1. Mol Cell Proteomics. 2007; 6: 845-859.
23. Liu Y, Liu W, Song XD, Zuo J. Effect of GRP75/mthsp70/PBP74/mortalin overexpression on intracellular ATP level, mitochondrial membrane potential and ROS accumulation following glucose deprivation in PC12 cells. Mol Cell Biochem. 2005; 268: 45-51.
24. Van Laar VS, Dukes AA, Cascio M, Hastings TG. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis. 2008; 29: 477-489.
25. Van Laar VS, Mishizen AJ, Cascio M, Hastings TG. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis. 2009; 34: 487-500.
26. Deocaris CC, Widodo N, Shrestha BG, et al. Mortalin sensitizes human cancer cells to MKT-077-induced senescence. Cancer Lett. 2007; 252: 259-269.
27. Widodo N, Deocaris CC, Kaur K, et al. Stress chaperones, mortalin, and pex19p mediate 5-aza-2' deoxycytidine-induced senescence of cancer cells by DNA methylation-independent pathway. J Gerontol. 2007; 62: 246-255.
28. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 2003; 6: 501-506.
29. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Sydney, Australia: Academic Press; 1986.
30. Schwarting RKW, Huston JP. Unilateral 6-hydroxy-dopamine lesions of mesostriatal dopamine neurons and their physiological sequelae. Prog Neurobiol. 1996; 49: 215-266.
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-254.
32. Puxeddu E, Susta F, Orvietani PL, et al. Identification of differentially expressed proteins in papillary thyroid carcinomas with V600E mutation of BRAF. Proteomics Clin Appl. 2007; 1: 672-680.
33. Susta F, Chiasserini D, Fettucciari K, et al. Protein expression changes induced in murine peritoneal macrophages by Group B Streptococcus. Proteomics. 2010; 10: 2099-2012.
34. Calabresi P, Saiardi A, Pisani A, et al. Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors. J Neurosci. 1997; 17: 4536-4544.
35. Costa C, Belcastro V, Tozzi A, et al. Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci. 2008; 28: 8040-8052.
36. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003; 987: 25-31.
37. Mazzio EA, Reams RR, Soliman KF. The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res. 2004; 1004: 29-44.
38. Massignan T, Casoni F, Basso M, et al. Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochem Biophys Res Commun. 2007; 353: 719-725.
39. Calabresi P, Centonze D, Pisani A, et al. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol. 1998; 43: 586-597.
40. Hoglinger GU, Lannuzel A, Khondiker ME, et al. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem. 2005; 95: 930-939.
41. Centonze D, Prosperetti C, Barone I, et al. NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. Exp Neurol. 2006; 202: 470-479.
42. Tozzi A, Tscherter A, Belcastro V, et al. Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology. 2007; 53: 783-789.
43. Park B, Yang J, Yun N, Choe KM, Jin BK, Oh YJ. Proteomic analysis of expression and protein interactions in a 6-hydroxydopamine-induced rat brain lesion model. Neurochem Int. 2010; 57: 16-32.
44. Witt SN. Hsp70 molecular chaperones and Parkinson's disease. Biopolymers. 2010; 93: 218-228.
45. Horst M, Oppliger W, Rospert S, Schonfeld HJ, Schatz G, Azem A. Sequential action of two hsp70 complexes during protein import into mitochondria. EMBO J. 1997; 16: 1842-1849.
46. Deocaris CC, Kaul SC, Wadhwa R. On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60. Cell Stress Chaperones. 2006; 11: 116-128.
47. Wagner I, Arlt H, van Dyck L, Langer T, Neupert W. Molecular chaperones cooperate with PIM1 protease in the degradation of misfolded proteins in mitochondria. EMBO J. 1994; 13: 5135-5145.
48. Taurin S, Seyrantepe V, Orlov SN, et al. Proteome analysis and functional expression identify mortalin as an antiapoptotic gene induced by elevation of [Na+]i/[K+]i ratio in cultured vascular smooth muscle cells. Circ Res. 2002; 91: 915-922.
49. Schwarzer C, Barnikol-Watanabe S, Thinnes FP, Hilschmann N. Voltage-dependent anion-selective channel (VDAC) interacts with the dynein light chain Tctex1 and the heat-shock protein PBP74. Int J Biochem Cell Biol. 2002; 34: 1059-1070.
50. Smith MP, Cass WA. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience. 2007; 144: 1057-1066.
51. Braak H, Del Tredici K. Nervous system pathology in sporadic Parkinson disease. Neurology. 2008; 70: 1916-1925.
52. Stephens B, Mueller AJ, Shering AF, et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience. 2005; 132: 741-754.
53. Day M, Wang Z, Ding J, et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci. 2006; 9: 251-259.